Clinical Trials Sponsored by Merck Sharp & Dohme LLC

Total 3951 results

Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Neuromuscular Blockade

United States, Austria, Belgium, Denmark, Germany
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
Merck Sharp & Dohme LLC

Completed

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Infectious Disease
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Hepatitis C Virus (HCV) Infection

France
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Melanoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

Tumor, Solid
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Renal Insufficiency

United States
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Anesthesia, General
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Merck Sharp & Dohme LLC

Completed

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

HIV-1 Infection

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (REALIZE)

Hyperlipoproteinemia Type II | Hypercholesterolemia, Familial
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Herpes Zoster
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

HIV-1
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

Neutropenia
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC

Completed

Effects of Insomnia on Simulated Driving (MK-0000-183-00)

Insomnia
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Urinary Tract Infections | Pyelonephritis
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Herpes Zoster | Herpes Zoster-related Complications
Merck Sharp & Dohme LLC

Unknown

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)

Mild Cognitive Impairment | Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

Hypersensitivity | Anaphylaxis
Merck Sharp & Dohme LLC

Completed

Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)

Migraine
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

Rheumatoid Arthritis (RA)
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)

Ulcerative Colitis

United Kingdom
Merck Sharp & Dohme LLC

Completed

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Hypertension
Merck Sharp & Dohme LLC

Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Atopic Dermatitis
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)

Anesthesia, General
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Type 2 Diabetes Mellitus

3

Subscribe